• 1.

    Sridhar VS, et al. Chronic kidney disease in type 1 diabetes: Translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes. Diabetologia 2024; 67:318. doi: 10.1007/s00125-023-06015-1

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy. ClinicalTrials.gov identifier: NCT02065791. Updated December 12, 2019. https://clinicaltrials.gov/study/NCT02065791

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2022; 102:S1S127. doi: 10.1016/j.kint.2022.06.008

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Agarwal R, et al.; FIDELIO-DKD and FIGARO-DKD Investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis. Eur Heart J 2022; 43:474484. doi: 10.1093/eurheartj/ehab777

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease. ClinicalTrials.gov identifier: NCT03819153. Updated April 30, 2024. https://clinicaltrials.gov/study/NCT03819153

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    ElSayed NA, et al.; on behalf of the American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of care in diabetes—2023. Diabetes Care 2023; 46(Suppl 1):S158S190. doi: 10.2337/dc23-S010

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Lee JF, et al. Cardiorenal protection in diabetic kidney disease. Endocrinol Metab (Seoul) 2021; 36:256269. doi: 10.3803/EnM.2021.987

  • 8.

    Neuen BL, et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation 2024; 149:450462. doi: 10.1161/CIRCULATIONAHA.123.067584

    • PubMed
    • Search Google Scholar
    • Export Citation

Management of Diabetic Kidney Disease: The Era of the Four Pillars

Vikas S. Sridhar Vikas S. Sridhar, MD, and David Z. I. Cherney, MD, PhD, are with the Toronto General Hospital Research Institute, University Health Network; Division of Nephrology, Department of Medicine, University Health Network; and the Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Search for other papers by Vikas S. Sridhar in
Current site
Google Scholar
PubMed
Close
and
David Z. I. Cherney Vikas S. Sridhar, MD, and David Z. I. Cherney, MD, PhD, are with the Toronto General Hospital Research Institute, University Health Network; Division of Nephrology, Department of Medicine, University Health Network; and the Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Search for other papers by David Z. I. Cherney in
Current site
Google Scholar
PubMed
Close
Restricted access
Save